A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site

Asuka Tsuya, Takayasu Kurata, Akihiro Tamiya, Isamu Okamoto, Shinya Ueda, Daisuke Sakai, Naotoshi Sugimoto, Koji Matsumoto, Isao Goto, Nobuyuki Yamamoto, Masahiro Fukuoka, Kazuhiko Nakagawa

研究成果: ジャーナルへの寄稿学術誌査読

1 被引用数 (Scopus)


Background Carcinomas of unknown primary site (CUPs) are heterogeneous tumors associated with a poor prognosis. This phase II trial was designed to evaluate the efficacy and safety of a novel combination chemotherapy of S-1 and cisplatin (CDDP) in patients with CUP. Patients and Methods Patients with previously untreated CUPs were eligible for this trial. The treatment schedule consisted of oral S-1 (40 mg/m2) twice a day on days 1-21, and intravenous CDDP (60 mg/m2) on day 8. This schedule was repeated every 5 weeks. Results A total of 46 patients were enrolled. The overall response rate and the disease control rate were 41.3 % and 80.4 %, respectively. The median overall survival time was 17.4 months. Grade 3/4 neutropenia, thrombocytopenia, and febrile neutropenia occurred in 28.3 %, 13.0 %, and 2.2 % of the patients, respectively. Conclusion CDDP plus S-1 combination chemotherapy is well tolerated and active first-line empiric therapies for patients with CUP.

ジャーナルInvestigational New Drugs
出版ステータス出版済み - 12月 2013

!!!All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 薬理学
  • 薬理学(医学)


「A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。